Article Abstract

Lung cancer recurrence epigenetic liquid biopsy

Authors: Alicia Hulbert, Ignacio Jusue-Torres


Lung cancer is the third most prevalent cancer after prostate and breast cancer in the US, having over 400,000 people diagnosed with the disease (1,2). It is the fifth overall leading cause of death in the world [after ischemic heart disease, stroke, lower respiratory infections and chronic obstructive pulmonary disease (COPD)] (3), and it is the primary cause of cancer-related death worldwide. Lung cancer accounts for almost 27% of all cancer-related deaths; and its 5-year survival does not reach 20% (1,2). Most of cases are diagnosed at late stages. Very recently, the National Lung Screening Trial (NLST) demonstrated that mortality reduction of lung cancer can be achieved by performing screening with low-dose computed tomography (CT) scans (4).

Article Options

Download Citation